Table 5.
Kinetics of apoB-48 in TRL during the placebo, extended-release niacin, or extended-release niacin plus lovastatin phases.
| TRL apoB-48 | |||
|---|---|---|---|
| Phase/subject | C *mg/dL | FCR*pools/d | PR*mg/kg d−1 |
| Placebo | |||
| 1 | 1.7 | 2.76 | 2.11 |
| 2 | 1.6 | 2.83 | 2.07 |
| 3 | 2.3 | 1.83 | 1.90 |
| 4 | 0.8 | 5.03 | 1.81 |
| 5 | 0.8 | 2.16 | 0.80 |
| Geometric mean | 1.33 | 2.74 | 1.64 |
| Niacin | |||
| 1 | 0.9 | 4.34 | 1.7 |
| 2 | 1.4 | 3.98 | 2.51 |
| 3 | 0.7 | 5.40 | 1.63 |
| 4 | 0.9 | 4.48 | 1.82 |
| 5 | 1.1 | 2.44 | 1.24 |
| Geometric mean | 0.96 | 4.00 | 1.73 |
| Niacin+Lovastatin | |||
| 1 | 0.7 | 4.95 | 1.56 |
| 2 | 0.8 | 3.57 | 1.33 |
| 3 | 1.0 | 3.42 | 1.49 |
| 4 | 1.1 | 3.22 | 1.59 |
| 5 | 0.5 | 4.31 | 1.03 |
| Geometric mean | 0.80 | 3.84 | 1.38 |
| Change (P value)1 | −0.45±0.78 (0.06) | +1.21±1.55 (0.04) | +0.04±0.39 (0.99) |
| Change (P value)2 | −0.62±0.63 (0.03) | +0.97±1.66 (0.10) | −0.34±0.37(0.36) |
| Change (P value)3 | −0.17±0.42 (0.97) | −0.23±1.52 (0.52) | −0.38±0.45 (0.35) |
*
variable was log-transformed before analysis
1: mean±SD of the difference between Niacin and Placebo (P value)
2: mean±SD of the difference between Niacin+Lovastatin and Placebo (P value)
3: mean±SD of the difference between Niacin+Lovastatin and Niacin (P value)